Knight Therapeutics, Inc.

Knight Therapeutics, Inc.

8.35
USD
-0.11
(-1.30%)
0.11EPS
65.52P/E
733.79MMarket Cap
Mar 25Next Earn

Total Valuation

USD

As of September 30, 2026, Knight Therapeutics Inc carries a market capitalization of 733.79M, placing it among publicly traded companies globally. Its enterprise value stands at 653.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap733.79M
Enterprise Value653.45M

Important Dates

Knight Therapeutics Inc's next confirmed earnings release is scheduled for March 25, 2027.

Earnings Date3/25/2027

Share Statistics

As of September 30, 2026, Knight Therapeutics Inc has 98.23M shares outstanding.

Shares Outstanding98.23M

Valuation Ratios

As of September 30, 2026, Knight Therapeutics Inc trades at a trailing price-to-earnings ratio of 65.52. The price-to-sales ratio is 1.86, and the price-to-book ratio stands at 1.31.

PE Ratio65.52
PS Ratio1.86
PB Ratio1.31
P/TBV Ratio2.96
P/FCF Ratio9.12
P/OCF Ratio7.98

Enterprise Valuation

As of September 30, 2026, Knight Therapeutics Inc trades at an EV/EBITDA multiple of 11.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 48.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Knight Therapeutics Inc trades at an EV/FCF ratio of 7.49, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 653.45M versus a market cap of 733.79M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.65
EV / EBITDA11.39
EV / EBIT48.43
EV / FCF7.49

Financial Position

As of September 30, 2026, Knight Therapeutics Inc maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.22, indicating elevated leverage, while an interest coverage ratio of 7.63 demonstrates adequate ability to service its debt obligations.

Current Ratio2.40
Quick Ratio1.61
Debt / Equity4.22
Debt / EBITDA0.41
Interest Coverage7.63

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Knight Therapeutics Inc posted a return on equity (ROE) of 2.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.96 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.52, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.98, useful for judging operating efficiency across full business cycles. The company generates approximately 477,111.28 in revenue per employee across its workforce of 830.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.04 indicates how many times Knight Therapeutics Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)2.05
Return on Assets (ROA)1.52
Return on Invested Capital (ROIC)1.96
Return on Capital Employed (ROCE)2.98
Revenue Per Employee477,111.28
Employee Count830.00
Inventory Turnover2.04

Taxes

USD

Over the twelve months ended September 30, 2026, Knight Therapeutics Inc recorded 1.73M in income tax expense. That works out to an effective tax rate of 13.33, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.96M, leaving 11.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.73M
Effective Tax Rate13.33

Stock Price Statistics

USD

As of the close on November 16, 2026, Knight Therapeutics Inc's stock has gained approximately 91.08% over the past 52 weeks. The 50-day moving average sits at 7.37, while the 200-day moving average is 5.47.

52-Week Price Change91.08%
50-Day Moving Average7.37
200-Day Moving Average5.47

Income Statement

USD

Over the twelve months ended September 30, 2026, Knight Therapeutics Inc generated 396.00M in revenue and converted that into 11.23M in net income, yielding earnings per share of 0.11. EBITDA reached 57.38M, while operating income came in at 21.99M.

Revenue396.00M
Gross Profit191.08M
Operating Income21.99M
Pretax Income12.96M
Net Income11.23M
EBITDA57.38M
EBIT13.49M
Earnings Per Share (EPS)0.11

Balance Sheet

USD

As of September 30, 2026, Knight Therapeutics Inc holds 103.90M in cash and equivalents against 23.56M in total debt, resulting in a net debt position of -69.15M. Total book value stands at 558.88M, with working capital of 180.85M providing operational flexibility.

Cash & Cash Equivalents103.90M
Total Debt23.56M
Net Debt-69.15M
Equity (Book Value)558.88M
Book Value Per Share5.69
Working Capital180.85M

Cash Flow

USD

Knight Therapeutics Inc produced 92.19M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -11.41M in capital expenditures, free cash flow totaled 80.78M - equivalent to 0.82 per share.

Operating Cash Flow92.19M
Capital Expenditures-11.41M
Free Cash Flow80.78M
FCF Per Share0.82

Margins

Over the twelve months ended September 30, 2026, Knight Therapeutics Inc posted a gross margin of 48.25, reflecting its pricing power and cost economics. The operating margin of 5.55 and net profit margin of 2.84 provide insight into operational efficiency.

Gross Margin48.25
Operating Margin5.55
Pretax Margin3.27
Profit Margin2.84
EBITDA Margin14.49

Dividends & Yields

Over the twelve months ended September 30, 2026, Knight Therapeutics Inc paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.96, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Knight Therapeutics Inc shareholders.

Shareholder Yield9.49
FCF Yield10.96

Scores

As of September 30, 2026, Knight Therapeutics Inc has an Altman Z-Score of 4.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.24